Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer

Adjuvant trastuzumab in HER2+ breast cancer reduces recurrence and mortality, and has been the standard treatment since 2006. The objective was to analyze health outcomes in the real world. Observational, retrospective study of patients with HER2+ breast cancer, stages I–III, treated with adjuvant t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lluch-Gómez, J., Núñez-Álvarez, V., de la Torre-Hita, C., Bernal-Gómez, M., Campini-Bermejo, A., Perdomo-Zaldívar, E., Rodríguez-Pérez, L., Calvete-Candenas, J., Martínez-Bautista, M. J., Benítez-Rodríguez, E., Baena-Cañada, J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156809/
https://www.ncbi.nlm.nih.gov/pubmed/37137963
http://dx.doi.org/10.1038/s41598-023-34429-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156809/
https://www.ncbi.nlm.nih.gov/pubmed/37137963
http://dx.doi.org/10.1038/s41598-023-34429-9

Ejemplares similares